173.55
-5.16 (-2.89%)
| Penutupan Terdahulu | 178.71 |
| Buka | 178.12 |
| Jumlah Dagangan | 1,318,321 |
| Purata Dagangan (3B) | 1,899,168 |
| Modal Pasaran | 28,965,494,784 |
| Harga / Pendapatan (P/E TTM) | 21.59 |
| Harga / Pendapatan (P/E Ke hadapan) | 14.04 |
| Harga / Jualan (P/S) | 1.84 |
| Harga / Buku (P/B) | 4.79 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 21 Jul 2026 |
| Margin Keuntungan | 7.88% |
| Margin Operasi (TTM) | 13.39% |
| EPS Cair (TTM) | 6.89 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -26.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 272.12% |
| Nisbah Semasa (MRQ) | 0.840 |
| Aliran Tunai Operasi (OCF TTM) | 2.62 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.45 B |
| Pulangan Atas Aset (ROA TTM) | 5.16% |
| Pulangan Atas Ekuiti (ROE TTM) | 19.79% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | IQVIA Holdings, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.50 |
|
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 1.05% |
| % Dimiliki oleh Institusi | 98.21% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 245.00 (Truist Securities, 41.17%) | Beli |
| Median | 217.00 (25.04%) | |
| Rendah | 210.00 (Barclays, 21.00%) | Beli |
| Purata | 222.25 (28.06%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 174.09 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| TD Cowen | 09 Mar 2026 | 213.00 (22.73%) | Beli | 178.55 |
| Barclays | 06 Mar 2026 | 210.00 (21.00%) | Beli | 174.49 |
| RBC Capital | 03 Mar 2026 | 221.00 (27.34%) | Beli | 173.96 |
| Truist Securities | 19 Feb 2026 | 245.00 (41.17%) | Beli | 169.36 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |